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Drug resistance is a complex and comprehensive 
problem of modern oncology that determines a num-
ber of failures during therapy of cancer patients. The 
study of mechanisms of the development of resistance 
to cancer preparations is important for understanding 
the way of correction of tumor cell phenotype toward 
elevation of its sensitivity to chemotherapy.
Due to the development of resistance, cells acquire 
new properties that are reflected at morphological level 
as well as on the change of their molecular, phenotypic 
and biochemical patterns [1–8]. That’s why compara-
tive study of biological patterns of sensitive cell and its 
resistant analog will help to identify the mechanisms 
of drug resistance development.
Cultivated lines of resistant cells of different his-
togenesis may serve as a convenient model for such 
research. The method of formation of drug resistance, 
a main method of experimental oncology, is grounded 
on prolonged cultivation of tumor cells in the medium 
with gradually increasing concentrations of anticancer 
preparations [9]. However, the method is associated 
with certain difficulties. Firstly, this process requires 
significant time period; for example, achievement 
of resistance to doxorubicin in human MCF-7 breast 
cancer cell line requires at least 4–5 months (resis-
tance level 16), to cisplatin — 7–8 months (resistance 
level 4), while the development of resistance to doxoru-
bicin in human A2780 ovarian cancer cell line occupies 
11–12 months (resistance level 6), and to cisplatin — 
6.5–8 months (resistance level 8). Secondly, drug 
resistance in human tumor is often characterized by 
cross-resistance to two and more anticancer prepa-
rations, while the mentioned method allows achieve 
the resistance only to one anticancer preparation at 
the time. Thirdly, further cultivation of resistant cells 
without addition of anticancer preparations leads to 
significant decrease of resistance level [9].
It is known that in blood plasma of patients with 
tumors of different localization elevated level of homo-
cysteine could be detected, and in some cases it may 
be explained by the development of drug resistance. 
Homocysteine is a sulfur-containing amino acid that 
is not present in natural proteins but is an intermediate 
product of exchange between amino acids methionine 
and cysteine [10–14]. According to the data of nume-
rous studies [15–22], elevated homocysteine content 
is directly linked to deficiency in methyl groups what in 
turn leads to hypomethylation. It is known that distur-
bance in DNA methylation map plays a role in regula-
tion of expression of genes [20–25], the protein prod-
ucts of which determine different mechanisms of drug 
resistance formation: functioning of transport systems 
(genes mdr1 [24–28], mrp1 [27–29], lrp [28, 29]) 
that results in decreased intracellular accumulation of 
cytostatic preparations; altered proteins — apoptosis 
regulators (genes p53 [29], bcl-2 [30, 31]); elevated 
activity of detoxification systems (genes GSTπ [31], 
MT [31–33]), system of DNA-adducts reparation (gene 
MGMT [33]) that appear during interaction of a number 
of anticancer preparations with DNA molecule, etc. So, 
the study of influence of elevated concentrations of ho-
mocysteine on the mechanisms of formation of drug 
resistance allows reveal the initial chains involved in 
the development of this process.
MATERIALS AND METHODS
Parental human MCF-7 breast cancer cells and 
A2780 ovarian cancer cells sensitive to anticancer 
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drugs (cisplatin and doxorubicin) were studied. Cis-
platin and doxorubicin were from Ebewe, Austria. The 
cells of both lines were cultured in modified Dulbecco 
ISCOV medium (Sigma, Germany) supplemented with 
10% of fetal calf serum (Sangva, Ukraine) at 37 °C 
in humidified 5% CO2. Cells were cultured for 24 h, and 
then homocysteine (Sigma, Germany) was added to 
culture medium at the concentrations of 50 or 100 mM. 
Incubation with homocysteine lasted for 72 h, then the 
cells were passaged, the cycle of abovementioned 
treatment was repeated 10 times, and then the cells 
were cultured for 3 months without homocysteine. The 
control cells of both lines were cultured without addition 
of homocysteine to culture medium.
Cytotoxicity test was performed after 1, 3, 5, and 
10 cycles of homocysteine treatment and after 3-months 
period of homocysteine-free cultivation using 3-[4,5-di-
methylthiazol-2–1]-2,5-diphenyltetrazolium bromide 
(Sigma, Germany) in standard MTT-test [34].
Expression of surface and intracellular protein 
(apoptosis regulator Bcl-2), proteins associated with 
drug resistance (glycoprotein (P-gp) and glutathione 
S-transferase (GST)), molecules of intercellular adhe-
sion (E-cadherins) was studied by immunocytochemi-
cal peroxydase-antiperoxydase (PAP) method using 
murine monoclonal antibodies (MAbs), secondary 
rabbit antibodies against mice immunoglobulins, and 
complex of MAbs against peroxydase with raddish 
peroxidase, and also EnVision visualization system 
(DakoCytomation, Denmark) [2, 35].
RESULTS AND DISCUSSION
It has been shown that 72 h incubation of ovarian can-
cer cells of A2780 line with homocysteine resulted in the 
decrease of their sensitivity to the action of cisplatin by 
2.5-fold, and to doxorubicin — by 2-fold, compared to the 
control cells, while 3rd treatment with homocysteine — by 
2.7-fold and 2.2-fold decrease, and after 5-th — 4.5-fold 
and 2.7 decrease, respectively. It’s necessary to note that 
further cultivation of the cells with homocysteine didn’t 
lead to elevation of their drug resistance level.
An acquirement of drug resistant phenotype in 
A2780 cells treated for long time with elevating concen-
trations of cisplatin occurs via antiapoptotic program [2] 
and is accompanied by an appearance of expression of 
Bcl-2 oncoprotein and GST — the protein responsible 
for intracellular detoxification (Fig. 1) [2]. Also, develop-
ment of resistance to doxorubicin in these cells occurs 
via induction of P-gp and E-cadherin expression (see 
Fig. 1) [2]. So, development of resistance to cisplatin 
and doxorubicin in cells of this histogenesis occurs via 
different mechanisms. That’s why immunocytochemical 
study of molecular profile of A2780 cells after long-term 
cultivation with homocysteine has been carried out, and 
has revealed that such treatment resulted in the induc-
tion of Bcl-2, P-gp, GST and E-cadherin expression 
(Fig. 2). This indicates that incubation of A2780 cells 
with homocysteine leads to simultaneous induction 
of expression of drug resistance markers which are 
common in cells resistant to cisplatin and doxorubicin, 
and intensity of immunocytochemical reaction (i. e. 
higher level of markers expression) elevates along with 
increasing number of passages.
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Fig. 1. Bcl-2 (a) and GST (b) expression in А2780/DDP cells, 
P-gp (c) and E-cadherin (d) expression in A2780/Dox cells
Incubation of MCF-7 cells with homocysteine for 
72 h resulted in the decrease of cells sensitivity to 
doxorubicin by 2.5-fold and to cisplatin — by 1.5-fold, 
compared to the control, while after third introduction 
of homocysteine into the culture medium the degree of 
MCF-cells resistance was equal to 3, and to cisplatin — 
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1.7, and after the fifth treatment these values were 
equal to 5.0 and 2.5 respectively. Further cultivation 
of MCF-7 cells with homocysteine had no additional 
impact on their resistance to mentioned drugs.
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Fig. 2. Bcl-2 (a), P-gp (b), GST (c) and E-cadherin (d) expression 
in А2780 cells with homocysteine-induced resistance
It is known that the development of drug resistance 
in MCF-7 cells upon action of elevating concentrations 
of cisplatin and doxorubicin is accompanied by the 
increase of cell adhesion (Fig. 3) [36]. Development 
of resistance to cisplatin in MCF-7 cells occurs via an-
tiapoptotic mechanisms (decreased Bcl-2 expression) 
and the system of intracellular detoxification (GST) [36], 
while doxorubicin-resistant MCF-7 cells acquire such 
properties via MDR-dependent mechanisms (elevated 
P-gp expression) (see Fig. 3).
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Fig. 3. Bcl-2 (a), GST (b) and E-cadherin (c) expression 
in MCF-7/DDP cells, P-gp (d) expression in MCF-7/Dox cells
Immunocytochemical study has demonstrated that 
incubation of MCF-7 cells with homocysteine resulted 
in the induction of P-gp, GST and E-cadherin expres-
sion and significant decrease of Bcl-2 (Fig. 4). So, our 
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data have shown that alteration of molecular profile of 
MCF-7 cells upon the action of homocysteine reflects 
an involvement of both mechanisms responsible for the 
development of resistance to cisplatin and doxorubicin.
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Fig. 4. Bcl-2 (a), GST (b), E-cadherin (c) and P-gp (d) expression 
in MCF-7 cells with homocysteine-induced resistance
It has been shown that further three months long 
cultivation of drug resistant cells in the medium without 
homocysteine doesn’t lead to decrease of resistance 
level.
So, cultivation of MCF-7 and A2780 cells with 
homocysteine leads to simultaneous development 
of resistance to doxorubicin and cisplatin. Increase 
of homocysteine concentration in culture medium 
over certain critical level causes maximal tension of 
systems of its utilization that can’t release the cell from 
its excess, what results in total genome demethylation 
upon conditions of deficiency of methyl groups donors, 
and consequently leads to elevation of activity of the 
majority of genes thus crea ting the grounds of tumor 
cell genetic instability.
Summarizing abovementioned, one should note 
that the creation of in vitro hyperhomocysteinemia 
model allows in 2–3 weeks receive cell strains with 
cross-resistance to doxorubicin and cisplatin. The 
recent studies have shown that the development of 
multidrug resistance phenotype involves a number 
of mechanisms and activation of respective genes; 
altered P-gp, GST and E-cadherin expression are di-
rectly linked to DNA methylation [13, 14, 37, 38]. From 
other hand, hypomethylation of DNA may be caused 
by disturbed metabolism of folic acids that leads to 
hyperhomocysteinemia.
Along with this, the mechanisms of formation of 
drug resistance upon elevated homocysteine level are 
far from being clear yet. Such process is associated 
with altered DNA methylation map (its hypomethyl-
ation) due to deficiency of methyl groups that appears 
as a result of compensatory elevation of activity of the 
systems of homocysteine utilization in response to its 
increased concentration in intracellular medium, and, 
possibly, due to inhibition of functions of DNA-methyl-
transferase-1 via deficiency of its substrate. Further 
studies of homocysteine-induced multidrug resistance 
in MCF-7 and A2780 cells will be required for under-
standing the ways to overcome natural and acquired 
drug resistance.
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